GlobeNewswire·Aug 24, 2026, 2:50 PM ET

Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately

Wolf Haldenstein Adler Freeman & Herz LLP filed a securities class action lawsuit in the U.S. District Court for the Southern District of California on behalf of investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD).
The class period covers the purchase of Aardvark securities between February 13, 2025, and May 14, 2026.
The lead-plaintiff deadline for the case is October 13, 2026.
The complaint alleges defendants failed to disclose that ARD-101 was less safe than represented, overstated clinical, regulatory, & commercial prospects, & issued materially false statements.
The alleged truth emerged on February 27, 2026, when Aardvark paused its Phase 3 HERO trial due to reversible cardiac observations in healthy volunteer studies.
Following the news, Aardvark's stock price fell $7.02 per share, or 56.2%, to close at $5.47 per share on March 2, 2026.
Wolf Haldenstein, founded in 1888, states there is no cost or obligation for affected investors to contact the firm regarding the investigation.
Investors may contact the firm via phone at (800) 575-0735 or (212) 545-4774, or by email at classmember@whafh.com.